All posts tagged
An Epigenetic Drug for Prostate Cancer Gets $26M to Enter Clinical Trials
This Oxford Biotech is Using DNA to Find New Peptide Drugs
British Biotech Raises £8.7M for White Blood Cell-Activating Cancer Vaccines
Where Does Brexit Leave European Biotech?
FDA Backs Gene Therapy for Fatal Neurodegenerative Childhood Disease
Biomarker Test for Crohn’s Disease Gets Massive Support From Wellcome Trust
The FDA Unanimously Recommends First Cannabinoid Treatment for Epilepsy
The 10 Biotech Companies in London to Keep an Eye on in 2018
Graphene Skin Patch Measures Blood Sugar Without a Needle
DNA Sequencing Unicorn Oxford Nanopore Raises £100M Round at £1.5Bn Valuation
Oxford Firm Develops Better Test for ALS Diagnosis
New Antibiotic for MRSA Infections is Ready for US Clinical Trials
Labiotech UG, All Rights Reserved -
This website uses
to give you the best experience. Agree by clicking the 'Accept' button.